Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2025-12-25 @ 4:25 AM
NCT ID:
NCT04726020
Eligibility Criteria:
Inclusion Criteria:
* Patients aged \>18;
* Solid cancer histological diagnosis on treatment with one of the listed medicines, defined by treatment type:
* Adjuvant chemotherapy:
* anthracyclines and cyclophosphamide ± taxanes (breast cancer)
* oxaliplatin e fluoropyrimidine (colon cancer)
* combination of platin or its derivate (lung cancer)
* First line oral target therapy:
* sunitinib, pazopanib (renal cancer)
* gefitinib, erlotinib,afatinib, crizotinib (lung cancer)
* vemurafenib ± comimetinib, dabrafenib±trametinib (Melanoma)
* everolimus ± exemestane (breast cancer)
* vandetanib o lenvatinib (thyroid cancer)
* vismodegib (skin basal cell carcinoma)
* imatinib (GIST)
* Immunotherapy:
* drugs anti CTLA4
* drugs antiPD1/PDL-1
* their combination
* sign of informed consent form;
* phone call availability and accessibility;
* life expectancy higher than 6 months.
Exclusion Criteria:
* Presence of cerebral symptomatic metastasis;
* Presence of neurological or psychiatric disease or other conditions that stop the protocol procedure compliance;
* Previous systemic cancer treatment. These exclusion criteria are justified because usually a systemic cancer treatment cause changes in toxicity profile. This means that these patients have higher attention on their toxicities and probably receive codified preventive treatments already.
* Participation in other clinical studies
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04726020
Study Brief:
Protocol Section:
NCT04726020